Transcutaneous immunotherapy via laser-generated micropores efficiently alleviates allergic asthma in Phl p 5-sensitized mice

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 67, Issue 11, 2012, Pages 1365-1374

  Bach, D ^a   Weiss, R ^a   Hessenberger, M ^a   Kitzmueller, S ^a   Weinberger, E E ^a   Krautgartner, W D ^a   Hauser Kronberger, C ^b   Boehler, C ^c   Thalhamer, J ^a   Scheiblhofer, S ^a  

^a UNIVERSITY OF SALZBURG   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c Pantec Biosolutions AG   (Liechtenstein)

Author keywords

allergy; immunotherapy; laser; micropores; transcutaneous

Indexed keywords

ALLERGEN; GRASS POLLEN ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CELL PROLIFERATION; CYTOKINE RELEASE; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HISTOLOGY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; IN VIVO STUDY; LASER; LASER GENERATED MICROPORE; LUNG FUNCTION; LUNG LAVAGE; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; SEROLOGY; SPLEEN CELL; SUBCUTANEOUS IMMUNOTHERAPY; SUPERNATANT; TH1 CELL; TH17 CELL; TH2 CELL; TRANSCUTANEOUS IMMUNOTHERAPY;

ADMINISTRATION, CUTANEOUS; AMINO ACID SEQUENCE; ANIMALS; ASTHMA; FEMALE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOTHERAPY; LASERS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; OVALBUMIN; PLANT PROTEINS; TH2 CELLS;

EID: 84867560483     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12005     Document Type: Article

References (46)

1. Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet 2006; 368: 733-743.
2. Calderon M, Cardona V, Demoly P,. One hundred years of allergen immunotherapy European academy of allergy and clinical immunology celebration: review of unanswered questions. Allergy 2012; 67: 462-476.
3. Freeman J,. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet 1911; 2: 814-817.
4. Noon L,. Prophylactic inoculation against hay fever. Lancet 1911; 2: 1572-1573.
5. Eifan AO, Shamji MH, Durham SR,. Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol 2011; 11: 586-593.
6. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62: 943-948.
7. Cox L, Calderon MA,. Subcutaneous specific immunotherapy for seasonal allergic rhinitis: a review of treatment practices in the US and Europe. Curr Med Res Opin 2010; 26: 2723-2733.
8. Werfel T,. Epicutaneous allergen administration: a novel approach for allergen-specific immunotherapy? J Allergy Clin Immunol 2009; 124: 1003-1004.
9. More DR, Hagan LL,. Factors affecting compliance with allergen immunotherapy at a military medical center. Ann Allergy Asthma Immunol 2002; 88: 391-394.
10. Frew AJ,. Allergen immunotherapy. J Allergy Clin Immunol 2010; 125 (Suppl 2): S306-S313.
11. Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, et al. Sub-lingual immunotherapy: World Allergy Organization position paper 2009. Allergy 2009; 64 (Suppl 91): 1-59.
12. Frew AJ,. Sublingual immunotherapy. N Engl J Med 2008; 358: 2259-2264.
13. Senna G, Lombardi C, Canonica GW, Passalacqua G,. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. J Allergy Clin Immunol 2010; 126: 668-669.
14. Razafindratsita A, Saint-Lu N, Mascarell L, Berjont N, Bardon T, Betbeder D, et al. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 2007; 120: 278-285.
15. Streilein JW,. Skin-associated lymphoid tissues (SALT): origins and functions. J Invest Dermatol 1983; 80 (Suppl): 12s-16s.
16. Gutowska-Owsiak D, Ogg GS,. The epidermis as an adjuvant. J Invest Dermatol 2012; 132: 940-948.
17. Kupper TS, Fuhlbrigge RC,. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004; 4: 211-222.
18. Steinman RM, Banchereau J,. Taking dendritic cells into medicine. Nature 2007; 449: 419-426.
19. Blamoutier P, Blamoutier J, Guibert L,. [Treatment of pollinosis with pollen extracts by the method of cutaneous quadrille ruling]. Presse Med 1959; 67: 2299-2301.
20. Pautrizel R, Cabanieu G, Bricaud H, Broustet P,. [Allergenic group specificity & therapeutic consequences in asthma; specific desensitization method by epicutaneous route]. Sem Hop 1957; 33: 1394-1403.
21. Agostinis F, Forti S, Di Berardino F,. Grass transcutaneous immunotherapy in children with seasonal rhinoconjunctivitis. Allergy 2010; 65: 410-411.
22. Dupont C, Kalach N, Soulaines P, Legoue-Morillon S, Piloquet H, Benhamou PH,. Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol 2010; 125: 1165-1167.
23. Mondoulet L, Dioszeghy V, Ligouis M, Dhelft V, Dupont C, Benhamou PH,. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy 2010; 40: 659-667.
24. Senti G, Graf N, Haug S, Ruedi N, von Moos S, Sonderegger T, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol 2009; 124: 997-1002.
25. Senti G, von Moos S, Tay F, Graf N, Sonderegger T, Johansen P, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012; 129: 128-135.
26. Von Moos S, Johansen P, Waeckerle-Men Y, Mohanan D, Senti G, Haffner A, et al. The contact sensitizer diphenylcyclopropenone has adjuvant properties in mice and potential application in epicutaneous immunotherapy. Allergy 2012; 67: 638-646.
27. Bachhav YG, Summer S, Heinrich A, Bragagna T, Bohler C, Kalia YN,. Effect of controlled laser microporation on drug transport kinetics into and across the skin. J Control Release 2010; 146: 31-36.
28. Yu J, Bachhav YG, Summer S, Heinrich A, Bragagna T, Bohler C, et al. Using controlled laser-microporation to increase transdermal delivery of prednisone. J Control Release 2010; 148: e71-e73.
29. Yu J, Kalaria DR, Kalia YN,. Erbium:YAG fractional laser ablation for the percutaneous delivery of intact functional therapeutic antibodies. J Control Release 2011; 156: 53-59.
30. Karnovsiky MJ,. A formaldehyde-glutaraldehyde fixative of high osmolarity for use in electron microscopy. J Cell Biol 1965; 27: 137A-138A.
31. Stoecklinger A, Grieshuber I, Scheiblhofer S, Weiss R, Ritter U, Kissenpfennig A, et al. Epidermal langerhans cells are dispensable for humoral and cell-mediated immunity elicited by gene gun immunization. J Immunol 2007; 179: 886-893.
32. Hartl A, Weiss R, Hochreiter R, Scheiblhofer S, Thalhamer J,. DNA vaccines for allergy treatment. Methods 2004; 32: 328-339.
33. Stoecklinger A, Scheiblhofer S, Roesler E, Lang A, Fastner G, Sedlmayer F, et al. T cell epitopes of the timothy grass pollen allergen Phl p 5 of mice and men and the detection of allergen-specific T cells using class II ultimers. Int Arch Allergy Immunol 2012; 158: 326-334.
34. Roesler E, Weiss R, Weinberger EE, Fruehwirth A, Stoecklinger A, Mostbock S, et al. Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens. J Allergy Clin Immunol 2009; 124: 1070-1077. e1071-1011.
35. Gabler M, Scheiblhofer S, Kern K, Leitner WW, Stoecklinger A, Hauser-Kronberger C, et al. Immunization with a low-dose replicon DNA vaccine encoding Phl p 5 effectively prevents allergic sensitization. J Allergy Clin Immunol 2006; 118: 734-741.
36. Weiss R, Hessenberger M, Kitzmueller S, Bach D, Weinberger EE, Krautgartner WD, et al. Transcutaneous vaccination via laser microporation. J Control Release 2012; [Epub ahead of print].
37. Taube C, Duez C, Cui ZH, Takeda K, Rha YH, Park JW, et al. The role of IL-13 in established allergic airway disease. J Immunol 2002; 169: 6482-6489.
38. Bal SM, Ding Z, van Riet E, Jiskoot W, Bouwstra JA,. Advances in transcutaneous vaccine delivery: do all ways lead to Rome? J Control Release 2010; 148: 266-282.
39. Senti G, Johansen P, Kundig TM,. Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol 2009; 9: 537-543.
40. Farage MA, Miller KW, Elsner P, Maibach HI,. Functional and physiological characteristics of the aging skin. Aging Clin Exp Res 2008; 20: 195-200.
41. Wesley NO, Maibach HI,. Racial (ethnic) differences in skin properties: the objective data. Am J Clin Dermatol 2003; 4: 843-860.
42. Bachhav YG, Heinrich A, Kalia YN,. Using laser microporation to improve transdermal delivery of diclofenac: increasing bioavailability and the range of therapeutic applications. Eur J Pharm Biopharm 2011; 78: 408-414.
43. Zech NH, Murtinger M, Uher P,. Pregnancy after ovarian superovulation by transdermal delivery of follicle-stimulating hormone. Fertil Steril 2011; 95: 2784-2785.
44. Senti G, von Moos S, Kundig TM,. Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy? Allergy 2011; 66: 798-809.
45. Jankovic D, Kugler DG, Sher A,. IL-10 production by CD4+ effector T cells: a mechanism for self-regulation. Mucosal Immunol 2010; 3: 239-246.
46. Strait RT, Morris SC, Finkelman FD,. IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking. J Clin Invest 2006; 116: 833-841.